Bailout stenting

Commentary: endovascular peripheral artery disease treatment: “leaving nothing behind?"

Endovascular treatment of peripheral artery disease (PAD) has become the standard of care for TransAtlantic Inter-Society Consensus II A,B patients, although no evidence exists as to which procedures are preferred for each lesion type, and numerous different approaches could be employed.1 The latest trend in this field is to revascularize the limb without stent deployment by means of angio-modeling,2 atherectomy,3 or drug-coated balloon angioplasty.4 Despite these efforts a certain number of patients with relatively short lesions will experience residual stenosis, elastic recoil, or resteno

Early experience with a new concept of angioplasty Nitinol-constrained balloon catheter (Chocolate®) in severely claudicant patients

BACKGROUND: To report our experience in treating severely claudicant patients, employing a "nitinol-constrained" balloon (Chocolate, TriReme Medical Inc., Pleasanton, CA-USA) before drug-coated balloon (DCB) in a standardized protocol. METHODS: Eighty-one (84 limbs) consecutive Rutherford category (RC) 3 patients treated between December 2014 and December 2016 for superficial femoral artery (SFA) and popliteal arterial (PA) disease by nitinol-constrained balloon followed by DCB were enrolled. Bailout stenting was performed by Zilver PTX implantation.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma